DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Active ingredient: Vincristine - Brands, Medical Use, Clinical Data

Brands, Medical Use, Clinical Data

Drug Category

  • Antineoplastic Agents

Dosage Forms

  • Liquid
  • Solution

Brands / Synonyms

22-Oxovincaleukoblastine; Indole alkaloid; LCR; Leurocristine; Onco TCS; Oncovin; Oncovin (1:1 sulfate salt); VCR; VIN; Vincaleukoblastine, 22-oxo-; Vincasar (1:1 sulfate salt); Vincasar PFS; Vincrex; Vincrex (1:1 sulfate salt); Vincristina [DCIT]; Vincristine; Vincristine Sulfate; Vincristine Sulfate PFS; Vincristinum [INN-Latin]; Vincrstine; Vincrystine; Vinkristin; Z-D-Val-Lys(Z)-OH

Indications

For treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, acute panmyelosis

Pharmacology

Vincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vincristine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vincristine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.

Mechanism of Action

The antitumor activity of Vincristine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis.

Absorption

Not Available

Toxicity

IVN-RAT LD50 1300 mg/kg; IPR-MUS LD50 5.2 mg/kg

Biotrnasformation / Drug Metabolism

Hepatic

Contraindications

Patients with the demyelinating form of Charcot-Marie-Tooth syndrome would not be given vincristine sulfate injection.

Drug Interactions

The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. Dosage adjustment should be based on serial blood level monitoring. The contribution of vincristine sulfate to this interaction is not certain. The interaction may result from reduced absorption of phenytoin and an increase in the rate of its metabolism and elimination.

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014